Lurasidone
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Apr 1, 2012 → Nov 1, 2013
NCT ID
NCT01566162About Lurasidone
Lurasidone is a phase 3 stage product being developed by Sumitomo Pharma for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01566162. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05213143 | Approved | Terminated |
| NCT05011669 | Approved | Completed |
| NCT01575561 | Phase 3 | Completed |
| NCT01620060 | Phase 1 | Completed |
| NCT01566162 | Phase 3 | Completed |
| NCT01423253 | Phase 3 | Completed |
| NCT01485640 | Phase 3 | Completed |
| NCT00868959 | Phase 3 | Completed |
| NCT01082289 | Phase 1 | Completed |
| NCT01082146 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia